Central Nervous System Infection by HIV-1: Special Emphasis to NeuroAIDS in India

Review

Abstract

Advent of combinatorial antiretroviral therapy has widely declined the number of HIV related deaths. It has however resulted in an increase in number of people living with HIV, and their morbidity in terms of their compromised brain functions, thereby worsening the overall scenario in the form of HIV associated neurocognitive impairment that are studied under the umbrella of neuroAIDS. Productively infected macrophages “hijack” brain parenchyma, resulting in slow neurodegeneration especially in the basal ganglia, hippocampus, prefrontal cortex and white matter. Although not directly infected, neurons undergo apoptosis via different pathways as discussed in the review. In addition, more devastating is the condition when HIV synergizes with drugs of abuse and brings in oxidative stress, elevation of inflammatory cytokines and increased calcium waves ultimately leading to augmented excitotoxicity. Mother to child transmission has been another important risk factor in the field of HIV rendering the neonates afflicted with severe neurodevelopmental delays and reduced immune response. Increase in several cytokines and other molecules have been promising in early diagnosis of the syndrome, but search for a biomarker is still on. In this review, we have outlined the recent developments in the field, practical challenges in neuroAIDS research and possible future directions that may help in better management of the disease.

Keywords

HIV dementia Clade specificity Drug abuse HAART Pediatric neuroAIDS Neurodegeneration Viral proteins 

References

  1. 1.
    Global report: UNAIDS report on the global AIDS epidemic, 2010Google Scholar
  2. 2.
    Department of AIDS Control, National AIDS Control Organisation, Ministry of Health & Family Welfare, Annual Report 2010–2011Google Scholar
  3. 3.
    Simoes EA, Babu PG, John TJ et al (1987) Evidence for HTLV-III infection in prostitutes in Tamil Nadu. Indian J Med Res 85:335–338PubMedGoogle Scholar
  4. 4.
    Antinori A, Arendt G, Becker JT et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799PubMedGoogle Scholar
  5. 5.
    Kaplan JE, Hanson D, Dworkin MS et al (2000) Epidemiology of Human Immunodeficiency Virus—associated opportunistic infections in the United States in the era of highly active antiretroviral therapy. Clin Infect Dis 30:S5–S14PubMedGoogle Scholar
  6. 6.
    Teja VD, Talasila SR, Vemu L et al (2005) Neurologic manifestations of HIV infection: an Indian hospital-based study. AIDS Read 15(3):139–143PubMedGoogle Scholar
  7. 7.
    Deshpande AK, Patnaik MM (2005) Nonopportunistic neurologic manifestations of the human immunodeficiency virus: an Indian study. MedGenMed 7(4):2PubMedGoogle Scholar
  8. 8.
    Xu J, Ikezu T (2009) The comorbidity of HIV-associated neurocognitive disorders and Alzheimer’s disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol 4(2):200–212PubMedGoogle Scholar
  9. 9.
    Gray F, Scaravilli F, Everall I et al (1996) Neuropathology of early HIV-1 infection. Brain Pathol 6:1–15PubMedGoogle Scholar
  10. 10.
    Valcour V, Shikuma C, Shiramizu B et al (2004) Higher frequency of dementia in older HIV-1 individuals: the Hawaii aging with HIV-1 cohort. Neurology 63(5):822–827PubMedGoogle Scholar
  11. 11.
    Bassel C, Rourke SB, Halman MH et al (2002) Working memory performance predicts subjective cognitive complaints in HIV infection. Neuropsychology 16(3):400–410PubMedGoogle Scholar
  12. 12.
    Gorman AA, Foley JM, Ettenhofer ML et al (2009) Functional consequences of HIV-associated neuropsychological impairment. Neuropsychol Rev 19(2):186–203PubMedGoogle Scholar
  13. 13.
    Maj M, Satz P, Janssen R et al (1994) WHO Neuropsychiatric AIDS study, cross-sectional phase II. Neuropsychological and neurological findings. Arch Gen Psychiatry 51(1):51–61PubMedGoogle Scholar
  14. 14.
    Rourke SB, Halman MH, Bassel C et al (1999) Neurocognitive complaints in HIV infection and their relationship to depressive symptoms and neuropsychological functioning. J Clin Exp Neuropsychol 21(6):737–756PubMedGoogle Scholar
  15. 15.
    Haase AT (1986) Pathogenesis of lentivirus infections. Nature 322:130–136PubMedGoogle Scholar
  16. 16.
    Peluso R, Haase A, Stowring L et al (1985) A Trojon horse mechanism for the spread of visna virus in monocytes. Virology 147:231–236PubMedGoogle Scholar
  17. 17.
    Simmons G, Reeves JD, McKnight A et al (1998) CXCR4 as a functional coreceptor for human immunodeficiency virus type 1 infection of primary macrophages. J Virol 72:8453–8457PubMedGoogle Scholar
  18. 18.
    Hibbitts S, Reeves JD, Simmons G et al (1999) Coreceptor ligand inhibition of fetal brain cell infection by HIV type 1. AIDS Res Hum Retroviruses 15:989–1000PubMedGoogle Scholar
  19. 19.
    Petito CK, Cash KS (1992) Blood-brain barrier abnormalities in the acquired immunodeficiency syndrome: immunohistochemical localization of serum proteins in postmortem brain. Ann Neurol 32:658–666PubMedGoogle Scholar
  20. 20.
    Moses AV, Nelson JA (1994) HIV infection of human brain capillary endothelial cells: implications for AIDS dementia. Adv Neuroimmunol 4:239–247PubMedGoogle Scholar
  21. 21.
    Gras G, Kaul M (2010) Molecular mechanisms of neuroinvasion by monocytes-macrophages in HIV-1 infection. Retrovirology 7:30–41PubMedGoogle Scholar
  22. 22.
    Minagar A, Shapshak P, Fujimura R et al (2002) The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 202:13–23PubMedGoogle Scholar
  23. 23.
    Dhillon NK, Williams R, Callen S et al (2008) Roles of MCP-1 in development of HIV-dementia. Front Biosci 13:3913–3918PubMedGoogle Scholar
  24. 24.
    Toborek M, Lee YW, Flora G et al (2005) Mechanisms of the blood-brain barrier disruption in HIV-1 infection. Cell Mol Neurobiol 25:181–199PubMedGoogle Scholar
  25. 25.
    Sporer B, Koedel U, Paul R et al (2000) Human immunodeficiency virus type-1 Nef protein induces blood–brain barrier disruption in the rat: role of matrix metalloproteinase-9. J Neuroimmunol 102:125–130PubMedGoogle Scholar
  26. 26.
    Williams KC, Corey S, Westmoreland SV et al (2001) Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 193:905–915PubMedGoogle Scholar
  27. 27.
    Cosenza MA, Zhao ML, Si Q et al (2002) Human brain parenchymal microglia express CD14 and CD45 and are productively infected by HIV-1 in HIV-1 encephalitis. Brain Pathol 12:442–455PubMedGoogle Scholar
  28. 28.
    Gorry PR, Ong C, Thorpe J et al (2003) Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res 1:463–473PubMedGoogle Scholar
  29. 29.
    Shi B, Girolami UD, He J et al (1996) Apoptosis induced by HIV-1 infection of the central nervous system. J Clin Investig 98:1979–1990PubMedGoogle Scholar
  30. 30.
    Xu Y, Kulkosky J, Acheampong E et al (2004) HIV-1-mediated apoptosis of neuronal cells: proximal molecular mechanisms of HIV-1-induced encephalopathy. PNAS 101(18):7070–7075PubMedGoogle Scholar
  31. 31.
    Levi G, Patrizio M, Bernardo A et al (1993) Human immunodeficiency virus coat protein gp120 inhibits the beta-adrenergic regulation of astroglial and microglial functions. PNAS 90(4):1541–1545PubMedGoogle Scholar
  32. 32.
    Benos DJ, Hahn BH, Shaw GM et al (1994) gp120-mediated alterations in astrocyte ion transport. Adv Neuroimmunol 4(3):175–179PubMedGoogle Scholar
  33. 33.
    Conant K, Demo AG, Nath A et al (1998) Induction of monocyte chemoattractant protein-1 in HIV-1 Tat-stimulated astrocytes and elevation in AIDS dementia. PNAS 95(6):3117–3121PubMedGoogle Scholar
  34. 34.
    Cinque P, Vago L, Mengozzi M et al (1998) Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. Aids 12(11):1327–1332PubMedGoogle Scholar
  35. 35.
    Rumbaugh J, Turchan-Cholewo J, Galey D et al (2006) Interaction of HIV Tat and matrix metalloproteinase in HIV neuropathogenesis: a new host defense mechanism. FASEB J 20(10):1736–1738PubMedGoogle Scholar
  36. 36.
    Haughey NJ, Mattson MP (2002) Calcium dysregulation and neuronal apoptosis by the HIV-1 proteins Tat and gp120. J Acquir Immune Defic Syndr 31(Suppl 2):S55–S61PubMedGoogle Scholar
  37. 37.
    Eugenin EA, King JE, Nath A et al (2007) HIV-tat induces formation of an LRP-PSD-95-NMDAR-nNOS complex that promotes apoptosis in neurons and astrocytes. PNAS 104(9):3438–3443PubMedGoogle Scholar
  38. 38.
    Qi M, Aiken C (2008) Nef enhance HIV-1 infectivity via association with the virus assembly complex. Virology 373(2):287–297PubMedGoogle Scholar
  39. 39.
    Levy DN, Refaeli Y, Weiner DB (1995) Extracellular Vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol 69(2):1243–1252PubMedGoogle Scholar
  40. 40.
    Patel CA, Mukhtar M, Pomerantz RJ (2000) Human immunodeficiency virus type 1 Vpr induces apoptosis in human neuronal cells. J Virol 74:9717–9726PubMedGoogle Scholar
  41. 41.
    Lannuzel A, Lledo PM, Lamghitnia HO et al (1995) HIV-1 envelope proteins gp120 and gp160 potentiate NMDA-induced [Ca2+]i increase, alter [Ca2+]i homeostasis and induce neurotoxicity in human embryonic neurons. Eur J Neurosci 7(11):2285–2293PubMedGoogle Scholar
  42. 42.
    Toggas SM, Masliah E, Mucke L et al (1996) Prevention of HIV-1 gp120-induced neuronal damage in the central nervous system of transgenic mice by the NMDA receptor antagonist memantine. Brain Res 706(2):303–307PubMedGoogle Scholar
  43. 43.
    Epstein LG, Gelbard HA (1999) HIV-1-induced neuronal injury in the developing brain. J Leukoc Biol 65(4):453–457PubMedGoogle Scholar
  44. 44.
    Okamoto S, Kang YJ, Brechtel CW et al (2007) HIV/gp120 decreases adult neural progenitor cell proliferation via checkpoint kinase-mediated cell-cycle withdrawal and G1 arrest. Cell Stem Cell 1(2):230–236PubMedGoogle Scholar
  45. 45.
    Krathwohl MD, Kaiser JL (2004) HIV-1 promotes quiescence in human neural progenitor cells. J Infect Dis 190(2):216–226PubMedGoogle Scholar
  46. 46.
    Mishra M, Taneja M, Malik S et al (2010) Human immunodeficiency virus type 1 Tat modulates proliferation and differentiation of human neural precursor cells: implication in neuroAIDS. J Neurovirol 16(5):355–367PubMedGoogle Scholar
  47. 47.
    Geretti AM (2006) HIV-1 subtypes: epidemiology and significance for HIV management. Curr Opin Infect Dis 19:1–7PubMedGoogle Scholar
  48. 48.
    Gurtlerr LG, Zekeng L, Tsague JM et al (1996) HIV-1 subtype O: epidemiology, pathogenesis, diagnosis and perspectives of the evolution of HIV. Arch Virol Suppl 11:195–202Google Scholar
  49. 49.
    Simon F, Mauclere P, Roques P et al (1998) Identification of a new human immune-deficiency virus type 1 distinct from group M and group O. Nat Med 4(9):1032–1037PubMedGoogle Scholar
  50. 50.
    Hu D, DonderoTJ, Mastro TD et al (1998) In: Wormser GP (ed) Global and molecular epidemiology of HIV. pp 27–40Google Scholar
  51. 51.
    Wainberg MA (2004) HIV-1 subtype distribution and the problem of drug resistance. AIDS 18(Suppl 3):S63–S68Google Scholar
  52. 52.
    Siddappa NB, Dash PK, Mahadevan A et al (2004) Identification of subtype C human immunodeficiency virus type 1 by subtype-specific PCR and its use in the characterization of viruses circulating in the southern parts of India. J Clin Microbiol 42(6):2742–2751PubMedGoogle Scholar
  53. 53.
    Tripathi SP, Kulkarni SS, Jadhav SD et al (2005) Subtype B and subtype C HIV type 1 recombinants in the northeastern state of Manipur, India. AIDS Res Hum Retroviruses 21(2):152–157Google Scholar
  54. 54.
    Gupta JD, Satishchandra P, Gopukumar K et al (2007) Neuropsychological deficits in human immunodeficiency virus type 1 clade C-seropositive adults from South India. J Neurovirol 13(3):195–202PubMedGoogle Scholar
  55. 55.
    Riedel D, Ghate M, Nene M et al (2006) Screening for HIV dementia in an HIV-infected population in India. J Neurovirol 12(1):34–38PubMedGoogle Scholar
  56. 56.
    Ranga U, Shankarappa R, Siddappa NB et al (2004) Tat protein of human immunodeficiency virus type 1 subtype C strains is a defective chemokine. J Virol 78(5):2586–2590PubMedGoogle Scholar
  57. 57.
    Li W, Huang Y, Reid R et al (2008) NMDA receptor activation by HIV-Tat protein is clade dependent. J Neurosci 28(47):12190–12198PubMedGoogle Scholar
  58. 58.
    Campbell GR, Watkins JD, Singh KK et al (2007) Human immunodeficiency virus type 1 subtype C Tat fails to induce intracellular calcium flux and induces reduced tumor necrosis factor production from monocytes. J Virol 81(11):5919–5928PubMedGoogle Scholar
  59. 59.
    Mishra M, Vetrivel S, Siddappa NB et al (2008) Clade-specific differences in neurotoxicity of human immunodeficiency virus-1 B and C Tat of human neurons: significance of dicysteine C30C31 motif. Ann Neurol 63(3):366–376PubMedGoogle Scholar
  60. 60.
    Rao VR, Sas AR, Eugenin EA et al (2008) HIV-1 clade-specific differences in the induction of neuropathogenesis. J Neurosci 28(40):10010–10016PubMedGoogle Scholar
  61. 61.
    Campbell GR, Loret EP, Spector SA et al (2010) HIV-1 clade B Tat, but not clade C Tat, increases X4 HIV-1 entry into resting but not activated CD4+ T cells. J Biol Chem 285(3):1681–1691PubMedGoogle Scholar
  62. 62.
    Wong JK, Campbell GR, Spector SA et al (2010) Differential induction of interleukin-10 in monocytes by HIV-1 clade B and clade C Tat proteins. J Biol Chem 285(24):18319–18325PubMedGoogle Scholar
  63. 63.
    Gandhi N, Saiyed Z, Thangavel S et al (2009) Differential effects of HIV type 1 clade B and clade C Tat protein on expression of proinflammatory and antiinflammatory cytokines by primary monocytes. AIDS Res Hum Retroviruses 25(7):691–699PubMedGoogle Scholar
  64. 64.
    Samikkannu T, Rao KV, Gandhi N et al (2010) Human immunodeficiency virus type 1 clade B and C Tat differentially induce indoleamine 2,3-dioxygenase and serotonin in immature dendritic cells: implications for neuroAIDS. J Neurovirol 16(4):255–263PubMedGoogle Scholar
  65. 65.
    Nath A, Hauser KF, Wojna V et al (2002) Molecular basis for interactions of HIV and drugs of abuse. J Acquir Immune Defic Syndr 31(Suppl 2):S62–S69PubMedGoogle Scholar
  66. 66.
    Solomon SS, Hawcroft CS, Narasimhan P et al (2008) Comorbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res 127:447–452PubMedGoogle Scholar
  67. 67.
    Hauser KF, Hahn YK, Adjan VV et al (2009) HIV-1 Tat and morphine have interactive effects on oligodendrocyte survival and morphology. Glia 57(2):194–206PubMedGoogle Scholar
  68. 68.
    Hauser KF, El-Hage N, Buch S et al (2005) Molecular targets of opiate drug abuse in neuroAIDS. Neurotox Res 8(1–2):63–80PubMedGoogle Scholar
  69. 69.
    El-Hage N, Gurwell JA, Singh IN et al (2005) Synergistic increases in intracellular Ca2+, and the release of MCP-1, RANTES, and IL-6 by astrocytes treated with opiates and HIV-1 Tat. Glia 50(2):91–106PubMedGoogle Scholar
  70. 70.
    El-Hage N, Wu G, Wang J et al (2006) HIV-1 Tat and opiate-induced changes in astrocytes promote chemotaxis of microglia through the expression of MCP-1 and alternative chemokines. Glia 53(2):132–146PubMedGoogle Scholar
  71. 71.
    Mahajan SD, Aalinkeel R, Reynolds JL et al (2005) Morphine exacerbates HIV-1 viral protein gp120 induced modulation of chemokine gene expression in U373 astrocytoma cells. Curr HIV Res 3(3):277–288PubMedGoogle Scholar
  72. 72.
    El-Hage N, Bruce-Keller AJ, Yakovleva T et al (2008) Morphine exacerbates HIV-1 Tat-induced cytokine production in astrocytes through convergent effects on [Ca(2+)](i), NF-kappaB trafficking and transcription. PLoS One 3(12):e4093PubMedGoogle Scholar
  73. 73.
    Peteron PK, Sharp BM, Gekker G et al (1990) Morphine promotes the growth of HIV-1 in human peripheral blood mononuclear cell cocultures. AIDS 4(9):869–873Google Scholar
  74. 74.
    Bagasra O, Pomerantz RJ (1993) Human immunodeficiency virus type 1 replication in peripheral blood mononuclear cells in the presence of cocaine. J Infect Dis 168(5):1157–1164PubMedGoogle Scholar
  75. 75.
    Roth MD, Tashkin DP, Choi R et al (2002) Cocaine enhances human immunodeficiency virus replication in a model of severe combined immunodeficient mice implanted with human peripheral blood leukocytes. J Infect Dis 185(5):701–705PubMedGoogle Scholar
  76. 76.
    Fitting S, Xu R, Bull C et al (2010) Interactive comorbidity between opioid drug abuse and HIV-1 Tat: chronic exposure augments spine loss and sublethal dendritic pathology in striatal neurons. Am J Pathol 177(3):1397–1410PubMedGoogle Scholar
  77. 77.
    Khurdayan VK, Buch S, El-Hage N et al (2004) Preferential vulnerability of astroglia and glial precursors to combined opioid and HIV-1 Tat exposure in vitro. Eur J Neurosci 19(12):3171–3182PubMedGoogle Scholar
  78. 78.
    Turchan JC, Dimayuga FO, Gupta S et al (2009) Morphine and HIV-Tat increase microglial-free radical production and oxidative stress: possible role in cytokine regulation. J Neurochem 108(1):202–215Google Scholar
  79. 79.
    Santos A, Cremades R, Rodriguez JC et al (2008) Mycobacterium peregrinum: bactericidal activity of antibiotics alone and in combination. J Infect Chemother 14(3):262–263PubMedGoogle Scholar
  80. 80.
    Pitcher J, Shimizu S, Burbassi S et al (2010) Disruption of neuronal CXCR4 function by opioids: preliminary evidence of ferritin heavy chain as a potential etiological agent in neuroAIDS. J Neuroimmunol 224(1–2):66–71PubMedGoogle Scholar
  81. 81.
    Avdoshina V, Biggio F, Palchik G et al (2010) Morphine induces the release of CCL5 from astrocytes: potential neuroprotective mechanism against the HIV protein gp120. Glia 58(13):1630–1639PubMedGoogle Scholar
  82. 82.
    Li Y, Wang X, Tian S et al (2002) Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 185(1):118–122PubMedGoogle Scholar
  83. 83.
    Potula R, Persidsky Y (2008) Adding fuel to the fire: methamphetamine enhances HIV infection. Am J Pathol 172(6):1467–1470PubMedGoogle Scholar
  84. 84.
    Nair MP, Mahajan SD, Schwartz SA et al (2005) Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J Immunol 174(11):6617–6626PubMedGoogle Scholar
  85. 85.
    Chana G, Everall IP, Crews L et al (2006) Cognitive deficits and degeneration of interneurons in HIV+ methamphetamine users. Neurology 67(8):1486–1489PubMedGoogle Scholar
  86. 86.
    Wilson JM, Kalasinsky KS, Levey AI et al (1996) Striatal dopamine nerve terminal markers in human, chronic methamphetamine users. Nat Med 2(6):699–703PubMedGoogle Scholar
  87. 87.
    Wilson JM, Levey AI, Bergeron C et al (1996) Striatal dopamine, dopamine transporter, and vesicular monoamine transporter in chronic cocaine users. Ann Neurol 40(3):428–439PubMedGoogle Scholar
  88. 88.
    Villemagne V, Yuan J, Wong DF et al (1998) Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C] WIN-35, 428 positron emission tomography studies and direct in vitro determinations. J Neurosci 18(1):419–427PubMedGoogle Scholar
  89. 89.
    Turchan J, Anderson C, Hauser KF et al (2001) Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2:3PubMedGoogle Scholar
  90. 90.
    Brown JM, Yamamoto BK (2003) Effects of amphetamines on mitochondrial function: role of free radicals and oxidative stress. Pharmacol Ther 99:45–53PubMedGoogle Scholar
  91. 91.
    Keller MA, Venkatraman TN, Thomas A et al (2004) Altered neurometabolite development in HIV-infected children: correlation with neuropsychological tests. Neurology 62(10):1810–1817PubMedGoogle Scholar
  92. 92.
    Boivin MJ, Green SD, Davies AG et al (1995) A preliminary evaluation of the cognitive and motor effects of pediatric HIV infection in Zairian children. Health Psychol 14(1):13–21PubMedGoogle Scholar
  93. 93.
    Dollard SC, James HJ, Sharer LR et al (1995) Activation of nuclear factor kappa B in brains from children with HIV-1 encephalitis. Neuropathol Appl Neurobiol 21(6):518–528PubMedGoogle Scholar
  94. 94.
    NACO news Oct–Dec 2006. Volume 2, issue 4Google Scholar
  95. 95.
    Spector SA (2001) Mother-to-infant transmission of HIV-1: the placenta fights back. J Clin Invest 107(3):267–269PubMedGoogle Scholar
  96. 96.
    Van AR, Harrington PR, Dow A et al (2007) Neurologic and neuro developmental manifestations of pediatric HIV/AIDS: a global perspective. Eur J Paediatr Neurol 11(1):1–9Google Scholar
  97. 97.
    Kamat A, Ravi V, Desai A et al (2009) Estimation of virological and immunological parameters in subjects from South India infected with human immunodeficiency virus type 1 clade C and correlation of findings with occurrence of neurological disease. J Neurovirol 15(1):25–35PubMedGoogle Scholar
  98. 98.
    Huang JS, Letendre S, Marquie-Beck J et al (2007) Low CSF leptin levels are associated with worse learning and memory performance in HIV-infected men. J Neuroimmune Pharmacol 2:352–358PubMedGoogle Scholar
  99. 99.
    Haughey NJ, Cutler RG, Tamara A et al (2004) Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 55(2):257–267PubMedGoogle Scholar
  100. 100.
    Roberts TK, Eugenin EA, Morgello S et al (2010) PrPC, the Cellular isoform of the human prion protein, is a novel biomarker of HIV-associated neurocognitive impairment and mediates neuroinflammation. Am J Pathol 176(6):2819–2830Google Scholar
  101. 101.
    Rezk NL, Tidwell RR, Kashuba AD (2003) Simultaneous determination of six HIV nucleoside analogue reverse transcriptase inhibitors and nevirapine by liquid chromatography with ultraviolet absorbance detection. J Chromatogr 791:137–147Google Scholar
  102. 102.
    De-Clercq E (2004) Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future. Chem Biodivers 1:44–64PubMedGoogle Scholar
  103. 103.
    Lalezari JP, Henry K, O’Hearn M et al (2003) Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 348:2175–2185PubMedGoogle Scholar
  104. 104.
    Yost R, Pasquale TR, Sahloff EG (2009) Maraviroc: a coreceptor CCR5 antagonist for management of HIV infection. Am J Health Syst Pharm 66:715–726PubMedGoogle Scholar
  105. 105.
    Barry M, Gibbons S, Back D et al (1997) Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations. Clin Pharmacokinet 32:194–209PubMedGoogle Scholar
  106. 106.
    Serrao E, Odde S, Ramkumar K et al (2009) Raltegravir, elvitegravir, and metoogravir: the birth of “me-too” HIV-1 integrase inhibitors. Retrovirology 6:25PubMedGoogle Scholar
  107. 107.
    Department of AIDS Control Ministry of Health and Family Welfare Government of India. Annual Report 2008–2009Google Scholar
  108. 108.
    Hogg R, Lima V, Sterne JA et al (2008) Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 372:293–299Google Scholar
  109. 109.
    Harrison KM, Song R, Zhang X (2010) Life expectancy after HIV diagnosis based on national HIV surveillance data from 25 states, United States. J Acquir Immune Defic Syndr 53:124–130PubMedGoogle Scholar
  110. 110.
    Liner KJ, Hall CD, Robertson KR et al (2008) Effects of antiretroviral therapy on cognitive impairment. Curr HIV/AIDS Rep 5(2):64–71PubMedGoogle Scholar
  111. 111.
    Sinha S, Mathews T, Arunodaya GR et al (2004) HIV-1 clade-C-associated “ALS”-like disorder: first report from India. J Neurol Sci 224(1–2):97–100PubMedGoogle Scholar
  112. 112.
    McArthur JC, Brew BJ, Nath A et al (2005) Neurological complications of HIV infection. Lancet Neurol 4(9):543–555PubMedGoogle Scholar
  113. 113.
    Heseltine PN, Goodkin K, Atkinson JH et al (1998) Randomized double-blind placebo-controlled trial of peptide T for HIV-associated cognitive impairment. Arch Neurol 55(1):41–51PubMedGoogle Scholar
  114. 114.
    Lipton SA, Chen HS (2004) Paradigm shift in neuroprotective drug development: clinically tolerated NMDA receptor inhibition by memantine. Cell Death Differ 11(1):18–20PubMedGoogle Scholar
  115. 115.
    Evans SR, Yeh TM, Sacktor N et al (2007) Selegiline transdermal system (STS) for HIV-associated cognitive impairment: open-label report of ACTG 5090. HIV Clin Trials 8(6):437–446PubMedGoogle Scholar
  116. 116.
    Eggert D, Dash PK, Gorantla S et al (2010) Neuroprotective activities of CEP-1347 in models of neuroAIDS. J Immunol 184(2):746–756PubMedGoogle Scholar
  117. 117.
    Horberg MA, Silverberg MJ, Hurley LB et al (2008) Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients. J Acquir Immune Defic Syndr 47:384–390PubMedGoogle Scholar
  118. 118.
    Everall IP, Bell C, Mallory M et al (2002) Lithium ameliorates HIV-gp120-mediated neurotoxicity. Mol Cell Neurosci 21:493–501PubMedGoogle Scholar
  119. 119.
    Smith SM (2005) Valproic acid and HIV-1 latency: beyond the sound bite. Retrovirology 2:56PubMedGoogle Scholar
  120. 120.
    Letendre S, Woods S, Ellis R et al (2006) Lithium improves HIV-associated neurocognitive impairment. AIDS 20:1885–1888PubMedGoogle Scholar
  121. 121.
    Kaul M, Lipton SA (2005) Experimental and potential future therapeutic approaches for HIV-1 associated dementia targeting receptors for chemokines, glutamate and erythropoietin. Neurotox Res 8(1–2):167–186PubMedGoogle Scholar
  122. 122.
    Dou H, Grotepas CB, McMillan JM et al (2009) Macrophage delivery of nanoformulated antiretroviral drug to the brain in a murine model of neuroAIDS. J Immunol 183(1):661–669PubMedGoogle Scholar
  123. 123.
    Saiyed ZM, Gandhi NH, Nair MP et al (2010) Magnetic nanoformulation of azidothymidine 5′-triphosphate for targeted delivery across the blood-brain barrier. Int J Nanomed 5:157–166Google Scholar
  124. 124.
    Hütter G, Nowak D, Mossner M et al (2009) Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N Engl J Med 360(7):692–698PubMedGoogle Scholar

Copyright information

© The National Academy of Sciences, India 2012

Authors and Affiliations

  1. 1.Cellular and Molecular NeuroscienceNational Brain Research Centre (NBRC), NH-8, Nainwal Mode, MANESARHaryanaIndia

Personalised recommendations